How I treat monoclonal gammopathy of renal significance (MGRS)

• Published in: Blood Vol. 122; no. 22; pp. 3583 - 3590
• Main Authors: Fermand, Jean-Paul, Bridoux, Frank, Kyle, Robert A., Kastritis, Efstathios, Weiss, Brendan M., Cook, Mark A., Drayson, Mark T., Dispenzieri, Angela, Leung, Nelson
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 21.11.2013; American Society of Hematology
• Subjects: Amyloidosis; Amyloidosis - complications; Amyloidosis - immunology; Amyloidosis - therapy; B-Lymphocytes; B-Lymphocytes - immunology; Cryoglobulinemia; Cryoglobulinemia - complications; Cryoglobulinemia - immunology; Cryoglobulinemia - therapy; Fanconi Syndrome; Fanconi Syndrome - etiology; Fanconi Syndrome - immunology; Fanconi Syndrome - therapy; Humans; Immunology; Kidney Diseases; Kidney Diseases - etiology; Kidney Diseases - immunology; Kidney Diseases - therapy; Life Sciences; Paraproteinemias; Paraproteinemias - complications; Paraproteinemias - immunology; Paraproteinemias - therapy
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2013-05-495929

Recently, the term monoclonal gammopathy of renal significance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development of kidney disease from those that are benign. By definition, patients with MGRS have B-cell clones that do not meet the definition of multiple myeloma or lymphoma. Nevertheless, these clones produce monoclonal proteins that are capable of injuring the kidney resulting in permanent damage. Except for immunoglobulin light chain amyloidosis with heart involvement in which death can be rapid, treatment of MGRS is often indicated more to preserve kidney function and prevent recurrence after kidney transplantation rather than the prolongation of life. Clinical trials are rare for MGRS-related kidney diseases, except in immunoglobulin light chain amyloidosis. Treatment recommendations are therefore based on the clinical data obtained from treatment of the clonal disorder in its malignant state. The establishment of these treatment recommendations is important until data can be obtained by clinical trials of MGRS-related kidney diseases.